Latest in News & Research

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

The topical pan-JAK inhibitor is the first FDA-approved therapy specifically indicated for chronic hand eczema

By Dermsquared Editorial Team | | August 06, 2025

40-Gene Expression Profile Predicts Local Recurrence in High-Risk cSCC

Three-year local recurrence-free survival, metastasis-free survival higher for class 1 versus class 2A or 2B patients

By Dermsquared Editorial Team | | August 04, 2025

Risk for New-Onset Depression, Anxiety Elevated for Patients With Hidradenitis Suppurativa

No consistent differences seen across severity levels using treatment and HS-related surgical procedures as markers of severity

By Dermsquared Editorial Team | | August 04, 2025

FDA Approves First Cream for Treating Chronic Hand Eczema

Key Takeaways

  • The U.S. Food and Drug Administration has given its nod to a new treatment for chronic hand eczema

  • Anzupgo is now the...

By Denise Mann (HealthDay News) | | August 04, 2025

Alopecia Areata Associated With Severe Psychosocial Impact

High levels of anxiety, depression, stigma, and impaired QoL reported by many patients; all linked to perceptions of illness

By Elana Gotkine (HealthDay News) | | August 04, 2025

Novel Treatments Recommended for Management of Atopic Dermatitis in Adults

Strong recommendations presented for tapinarof cream, roflumilast cream, lebrikizumab, nemolizumab with concomitant topical therapy

By Elana Gotkine (HealthDay News) | | August 04, 2025

Daily Emollient Application May Reduce Risk for Atopic Dermatitis in Infants

Daily emollient applications starting before age 9 weeks linked to reduction in cumulative incidence of atopic dermatitis at age 24 months

By Dermsquared Editorial Team | | July 25, 2025

Factors Identified That Affect Dermoscopic Findings in Acral Melanoma

Tumor thickness, lesion diameter, patient sex, and patient age may affect dermoscopic findings

By Dermsquared Editorial Team | | July 25, 2025

Study Compares Benefits, Harms of Treatments for Chronic Hives

Systematic review and network meta-analysis included 93 trials evaluating 42 interventions

By Lori Solomon (HealthDay News) | | July 25, 2025

Subclinical Synovitis Risk Higher in Psoriasis Without Musculoskeletal Involvement

Authors say imaging may aid in identifying individuals at risk for progression to psoriatic arthritis

By Lori Solomon (HealthDay News) | | July 25, 2025

Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma

80 percent of adult patients with stage III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment

By Elana Gotkine (HealthDay News) | | July 25, 2025

Number of Atopic Dermatitis Flares Linked to Lower QoL, More Severe Disease

Flare severity, duration, and number were among most important predictors of AD severity

By Dermsquared Editorial Team | | July 18, 2025

Neutrophil-to-Lymphocyte Ratio Can ID Risk in Localized Melanoma

NLR level >4.8 associated with increased risk for melanoma-specific death and developing distant metastases

By Dermsquared Editorial Team | | July 18, 2025

High Dietary Inflammatory Index Tied to Increased Prevalence of Eczema

Significant sex interaction observed, with stronger associations in the female group

By Elana Gotkine (HealthDay News) | | July 18, 2025

Atopic Dermatitis May Be Linked to Increased Risk for CKD

Association between AD and increased risk for chronic kidney disease seen for men and women and in all age groups

By Elana Gotkine (HealthDay News) | | July 18, 2025

Prevalence, Incidence of Eczema Increase With Severity of Alopecia Areata

Those with moderate-to-severe versus mild AA had 78 percent higher risk for being diagnosed with atopic dermatitis

By Elana Gotkine (HealthDay News) | | July 18, 2025

Ichthyosis Scoring System Can Be Applied Across Phototypes

Excellent interrater intraclass correlation coefficients seen for individuals with Fitzpatrick I to III, IV to VI skin types

By Dermsquared Editorial Team | | July 11, 2025

Distinct Risk Factors Seen for Nevus-Associated, De Novo Melanomas

Significantly higher hazard ratios seen for NAM than de novo melanoma for high nevus density, high genetic propensity for melanoma development

By Dermsquared Editorial Team | | July 11, 2025

AI Better for Tumor-Infiltrating Lymphocyte Quantification in Melanoma Than Traditional Methods

Machine learning algorithm has superior reproducibility and prognostic associations compared with traditional pathologist-read methods

By Elana Gotkine (HealthDay News) | | July 11, 2025

Review Compares Efficacy, Safety of Treatments for Hidradenitis Suppurativa

Differences between adalimumab and other targeted treatments mainly not significant

By Elana Gotkine (HealthDay News) | | July 11, 2025

Extending Dabrafenib + Trametinib Beneficial in Stage III Melanoma

Extending adjuvant dabrafenib + trametinib beyond one year linked to better relapse-free survival

By Dermsquared Editorial Team | | July 02, 2025

Increased Levels of Environmental Pollutants Linked to Atopic Dermatitis

Probable associations seen for secondhand smoking exposure and traffic and industrial plant exposure with increased prevalence of atopic dermatitis

By Dermsquared Editorial Team | | July 02, 2025

Men With Hidradenitis Suppurativa Perceive Better Physician Communication

Female patients perceive that clinicians are significantly worse at demonstrating respect, listening, and explaining concepts

By Elana Gotkine (HealthDay News) | | July 02, 2025

24 of 1274

Headline from the Week of August 17 - 23, 2026

Peripheral Globules, Related Lesion Dynamics Predict Outcomes in Melanocytic Nevi

By Dermsquared Editorial Team | | August 18, 2026

Upadacitinib Has Positive Benefit-Risk Profile for Severe Alopecia Areata

By Dermsquared Editorial Team | | August 18, 2026